Amneal is a dynamic pharmaceutical company. Fresh off the heels of a recent combination with Impax Laboratories, we’re evolving and integrating our business to drive greater success and to meet changing healthcare needs. We’re looking for entrepreneurial-minded team players who want to join hearts and minds in our quest to make healthy possible.

We are looking for individuals who bring innovative ideas, a willingness to challenge the status quo and a focus on delivering value and results. We also look for people who enjoy their work, want to grow with us, engage in our Responsibility commitments and make a difference for our company, our patients and our shareholders.

We offer opportunities across our development, manufacturing, marketing and corporate support functions.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Following our recent combination with Impax Laboratories, we are building one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Today’s healthcare environment requires a new approach and new ideas. While staying true to our reputation for quality, service and value, we are reinventing our processes, our playbook and our creative partnerships. We are focused on delivering outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow’s health challenges.

Our broad portfolio is the foundation from which we make healthy possible. In the US, our generics portfolio of approximately 200 generic product families* provides patients with more affordable access to quality medicines. Our growing Specialty Pharma business, operating as Impax , delivers products that meet important medical needs in central nervous system disorders, parasitic infections and other therapeutic categories. We are also excited about our work to bring patients more affordable biologic therapy options through our biosimilars program, which today includes one filed product and one near-term filing opportunity.